Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT3A | P56704 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 10/20 | 0.48 |
| ▸ | CDK4 | P11802 | 3/20 | 0.43 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | QDPR | P09417 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3706873 | 0.84 | NAMPT (0.67) | NAMPTSIGMAR1HTR2CQDPRHTR6 | |
| SCHEMBL3701332 | 0.83 | NAMPT (0.72) | WNT3ANAMPT | |
| SCHEMBL24267829 | 0.79 | WNT3A (0.59) | WNT3ANAMPTCDK4CDK6SIGMAR1 | |
| SCHEMBL3701244 | 0.78 | NAMPT (0.48) | WNT3ANAMPTHTR6 | |
| Hydrochloric Acid SCHEMBL29771347 | 0.78 | WNT3A (0.58) | WNT3ANAMPTCDK4CDK6SIGMAR1 | |
| SCHEMBL24671307 | 0.74 | WNT3A (0.54) | WNT3ANAMPTCDK4CDK6SIGMAR1 | |
| SCHEMBL3707742 | 0.71 | RAB9A (0.56) | — | |
| SCHEMBL29803282 | 0.69 | CCNT1 (0.49) | WNT3ANAMPTCDK4CDK6HTR2C | |
| SCHEMBL29803621 | 0.69 | QDPR (0.54) | WNT3ACDK4CDK6QDPR | |
| Trifluoroacetic Acid SCHEMBL29803488 | 0.69 | WNT3A (0.49) | WNT3ANAMPTCDK4CDK6SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10093624-B2 | NAMPT and ROCK inhibitors | ABBVIE INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-9302989-B2 | NAMPT and rock inhibitors | ABBVIE INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20160031880-A1 | Nampt and Rock Inhibitors | ABBVIE INC. (US) | 2016-02-04 | — | — | US | disclosed |
| EP-2640698-A1 | NAMPT AND ROCK INHIBITORS | AbbVie Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012067965-A1 | NAMPT AND ROCK INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20120122842-A1 | NAMPT AND ROCK INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10093624-B2 | NAMPT and ROCK inhibitors | NAMPT, NNMT, NADK | WNT3A 3702/4885NAMPT 1/4885CDK4 1531/4885 |
| US-20120122842-A1 | NAMPT AND ROCK INHIBITORS | NAMPT, NNMT, NME2 | WNT3A 2849/4885NAMPT 1/4885CDK4 2883/4885 |
| US-20160031880-A1 | Nampt and Rock Inhibitors | NAMPT, NNMT, NME2 | WNT3A 2849/4885NAMPT 1/4885CDK4 2883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.